At Ancora Heart, we know there are countless heart failure and FMR patients with no cure in sight. Our innovation brings us closer to achieving an unprecedented method for improving their quality of life.

ABOUT US

Ancora Heart

We are a medical device company based in Santa Clara, CA, dedicated to helping people with heart failure and functional mitral regurgitation (FMR) feel better and live longer.

We developed AccuCinch®, the first percutaneous ventricular repair (PVR) system designed to treat FMR, which is caused by heart failure. AccuCinch targets dysfunction of the left ventricle, which is the underlying cause of FMR. Unlike current surgical or transcatheter procedures that replace or repair an otherwise-normal mitral valve, AccuCinch repairs the left ventricle to reduce FMR and improve quality of life for heart failure patients.

Today, the outlook for FMR patients can be characterized as a progressive decline, because a majority of patients are treated with medications that have poor survival rates. Heart failure costs the U.S. an estimated $30.7 billion each year in health care services, medications to treat heart failure, and missed days of work.1 Because of the aging population, the total number of Americans living with HF is expected to increase by 46% to 8.5 million in 2030, and the cost of care will more than double to $69.7 billion.1

Up to 74% of people with heart failure also suffer from FMR, a condition caused when the left ventricle of the heart becomes enlarged to the point where it pulls the mitral valve leaflets apart and allows blood to flow backwards into the atrium.2 Most existing therapies only address the symptoms of FMR. Every year thousands of HF and FMR patients find that the disease has progressed beyond the ability for medications and pacemakers to manage symptoms, but less than 11% are candidates for mitral valve surgery.3

AccuCinch is the first first percutaneous ventricular repair (PVR) system designed to treat FMR to bring hope to the millions of patients with limited options today.

  • Footnotes

    1 Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.
    2 Al-Amri, H. S., Al-Moghairi, A. M., & El Oakley, R. M. (2011). Surgical treatment of functional mitral regurgitation in dilated cardiomyopathy. Journal of the Saudi Heart Association, 23(3), 125–134. http://doi.org/10.1016/j.jsha.2011.04.001
    3 Zainab Samad, et al.; Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction, European Heart Journal, Volume 36, Issue 40, 21 October 2015, Pages 2733–2741, https://doi.org/10.1093/eurheartj/ehv343

In 2030, the total number of Americans living with heart failure is expected to increase by 46%

graphImage.alt

Our Team

Jeffrey M. Closs

President and CEO

Mr. Closs brings proven leadership in medical devices, health policy, and technology to the Ancora Heart team. He has dedicated his career to working at the intersections of change to promote innovative, life-changing solutions. He has extensive experience founding new ventures (Benu), driving a successful IPO (Perclose), and having leadership roles at Fortune 500 companies (Fox Hollow, Edwards, Guidant, Bentley). Formerly a director at Nellix Endovascular, which was acquired by Endologix, and BioIQ, a health tech company, he is also an adjunct professor at Stanford University Center for Health Policy and the former president of the St. Raymond School Board. Mr. Closs holds an MBA from Emory University and a BA from the University of California, Los Angeles.

Russel Sampson

Chief Technical Officer

A champion for the development of minimally invasive surgical systems, Mr. Sampson brings a proven track record of invention (over 80 U.S. international patents) to his position at Ancora Heart. Leveraging his deep experience with CE and PMA approvals, commercialization, profitability and acquisition for companies such as Cytyc, Novacept, Abbott Laboratories, Space Systems/Loral and Ford Aerospace, he is responsible for our core technology, intellectual property and product development efforts. Mr. Sampson is the co-founder of Sierra Surgical Technologies (SST) and holds a BS in Mechanical Engineering (AMES) from the University of California, San Diego.

Michael Zapien

Senior Director of Clinical Affairs

Drawing on his expertise in transitioning innovative medical devices from the developmental stage to commercial success at several emerging startups (Elixir, Nanostim), Mr. Zapien leads our clinical research. Previously the Director of Clinical and Medical Affairs at CardioDx, Inc., he also has clinical and commercial experience at Medi-Globe, Silk Road Medical, Abbott Vascular, and Guidant Corp. Mr. Zapien is a certified clinical researcher with a MS from the University of Maryland and a BS from San Francisco State University.

Our Board of Directors

IN THE MEDIA

Current Press

BUSINESS WIRE
October 31, 2016

Guided Delivery Systems Announces Senior Leaders and Company Name Change to Ancora Heart

SANTA CLARA, Calif. Guided Delivery Systems Inc., a company developing a novel treatment to address heart failure and functional mitral regurgitation, today announced Jeffrey M. Closs has assumed the role of President and CEO and the company has completed a name change to Ancora Heart, Inc.

Read More

To Learn More

GET IN TOUCH